A highly conductive electrochemical sensor was constructed for the simultaneous electrochemical determination of levodopa and piroxicam by modification of a glassy carbon electrode with a ZnO-Pd/CNT nanocomposite (GCE/ZnO-Pd/CNTs). The ZnO-Pd/CNT nanocomposite was synthesized by the sol-gel procedure and was characterized by EDAX, MAP and SEM. The sensor was shown to improve the oxidation signal of levodopa and piroxicam by ∼70.2-fold and ∼41.5-fold, respectively. This marks the first time that the electrochemical behavior of levodopa and piroxicam have been investigated at the surface of GCE/ZnO-Pd/CNTs. The voltammogram showed a quasi-reversible signal and an irreversible redox signal for electro-oxidation of levodopa and piroxicam, respectively. The GCE/ZnO-Pd/CNTs showed a linear dynamic range of 0.6 to 100.0 μM (at a potential of ∼180 mV) and 0.1 to 90 μM (at a potential of ∼480 mV) with detection limits of 0.08 and 0.04 μM for the determination of levodopa and piroxicam, respectively. GCE/ZnO-Pd/CNTs were then applied for the determination of levodopa and piroxicam in real samples.
No takes yet. Share an insight, caveat, or question.
Karimi‐Maleh et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: